$3.5 million for preventing and managing chronic diseases in Québec - The FRSQ, MSSS and Pfizer announce funding for five chronic disease research projects

QUEBEC CITY, Jan. 24 /CNW Telbec/ - The Fonds de la recherche en santé du Québec (FRSQ), in partnership with the Ministère de la Santé et des Services sociaux (MSSS) and the pharmaceutical company Pfizer Canada, announces the first series of projects chosen in connection with the Pfizer-FRSQ-MSSS Chronic Disease Fund.

Created thanks to an investment of $5 million from Pfizer Canada, this FRSQ-coordinated research grant program is aimed at evaluating chronic disease prevention and management initiatives, supporting them financially, fostering, where appropriate, their implementation throughout Quebec, and making our healthcare system more efficient.

Of the different projects submitted, five were recommended for funding, namely, those of the CSSS Champlain, the CSSS de Chicoutimi, the CSSS de Laval, the CSSS du Rocher-Percé and the CSSS du Sud-Ouest-Verdun. This announcement concerns investments totalling nearly $3.5 million over the next two years.

All projects submitted to the Pfizer-FRSQ-MSSS Chronic Disease Fund should be in line with the Ministère de la Santé et des Services sociaux' chronic disease goals, be primary care initiatives for promoting the integration of chronic disease prevention and management, and focus on changing clinical practices. In accordance with the FRSQ's current rules and procedures, the applications were examined by a scientific review committee consisting of experts from scientific and clinical settings.

"Chronic diseases pose a significant challenge to all of Quebec society, a challenge that is growing with the aging of the province's population. With this new program, we hope to encourage primary care initiatives that will foster chronic disease prevention and management in order to evaluate them using a scientific approach and to pass the benefits on to other settings throughout Quebec," says Yves Joanette, President and Chief Executive Officer of the Fonds de la recherche en santé du Québec.

"This is a very innovative type of research program, for it includes both an innovative clinical component and an evaluative research component. Collaboration between health professionals and researchers is a unique opportunity to recognize and disseminate original chronic disease prevention and management initiatives throughout Quebec, adds Dr. Howard Bergman, Vice-President of Scientific Affairs at the Fonds de la recherche en santé du Québec.

"At Pfizer, we believe that it takes more than medication to improve chronic disease management. Strongly committed to improving people's health, we are proud to partner with the FRSQ and the MSSS to stimulate health innovation. This initiative attests to Pfizer Canada's desire to maintain its involvement in the development of research and once again reaffirms its commitment to the government's chronic disease priorities," says Paul Lévesque, President of Pfizer Canada.

About the Fonds de la recherche en santé du Québec (FRSQ)
The mission of the Fonds de la recherche en santé du Québec (FRSQ), which reports to the Minister of Economic Development, Innovation and Export Trade, is to support health research in order to foster the wellness of Quebecers. Its mandate is to promote and financially support this research, to share knowledge and train researchers, as well as to establish partnerships necessary for the development of Quebec's research and innovation system and advance the research internationally. For additional information: www.frsq.gouv.qc.ca

About Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian division of Pfizer Inc., the world's leading biopharmaceutical company. The company is one of the largest contributors to health research in Canada. Pfizer's diversified healthcare portfolio includes human and animal biologics, small-molecule medicines and vaccines, nutritional products and many of the world's best-known consumer products.

Every day, Pfizer Canada employees work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medication to be truly healthy. To learn more about Pfizer's More Than Medication philosophy and programs, visit morethanmedication.ca. To learn more about Pfizer Canada, visit pfizer.ca.

List of Funded Projects

CSSS Champlain - $699,040
The intersectorial and interprofessional type 2 diabetes follow-up proposed in this project improves the continuum of services that has been in place for over two years in the Réseau local de services Champlain thanks to the collaborative efforts between the network's family physicians and the primary health care teams at the CSSS Champlain and Charles LeMoyne Hospital. This improvement involves an increase in the number of family physicians who provide this follow-up, the inclusion of community pharmacists in the care team, and a more systematic evaluation of diabetes-related risks for individuals aged 45 and up.

CSSS de Chicoutimi - $699,800
This project is aimed at implementing an intervention that will constitute an improvement, an adaptation and a permanent part of the services provided by the Trajectoire des services de réadaptation intégrés pour maladies chroniques du Saguenay-Lac-St-Jean (a regional initiative offering a range of activities pertaining to issues such as diet, physical activity and smoking cessation) in primary care settings in the Chicoutimi and Jonquière regions, whose CSSSs are partners in this proposal. The project relies on the success of the Trajectoire's previous operations, on regional mobilization, and on the experience acquired within the teams.

CSSS de Laval - $636,282
Laval's healthcare community created the TRANSIT program, which is aimed at TRANSforming InTerprofessional practices with a view to improving the quality of cardiovascular preventive care at the primary care level. The overall objective of the project is to institute the TRANSIT program at a family medicine group in order to improve care and service coordination through a pivot nurse in a context of interprofessional collaboration, to facilitate access to the services of nutritionists and kinesiologists, to improve self-management support for patients and their families, and to improve the management of clinical information.

CSSS du Rocher-Percé - $699,928
This project, with the theme of managing one's health in the Rocher-Percé region, is characterized by two major innovations. The delivery of interventions prescribed as part of individualized interdisciplinary service plans is based on a group physical activity program which takes place regularly in four localities in the region and at points of delivery as unconventional as private gyms. In addition, the consolidation of the technological tools currently in use will continue to facilitate home follow-up, and a new software program will facilitate the decentralization of practice settings and interdisciplinary follow-up by permitting the real-time sharing of clinical information.

CSSS du Sud-Ouest-Verdun (in charge) and five partnering CSSSs1 - $700,000  
Continue implementing an integrated, interdisciplinary cardiometabolic risk prevention and management program for the purpose of assisting primary care general practitioners in managing people with diabetes and/or hypertension, and take action on health determinants, for example, the way lifestyle habits affect diabetes and hypertension, in order to delay disease progression.

The Pfizer-FRSQ-MSSS Chronic Disease Fund

The purpose of the Fund, valued at $5 million, is to finance chronic disease prevention and management projects and evaluate such projects.

In collaboration with one or more family physicians and the health and social services research community, CSSSs are invited to submit projects that will promote the interdisciplinary follow-up of people with chronic diseases or the implementation of self-management tools and approaches. 

The applications were examined by a scientific review committee consisting of experts from scientific and clinical settings. All the projects chosen include a clinical component and an evaluative research component. Priority is given to projects that are already operational, ready to be implemented or in the process of being implemented.

Chronic Diseases in Quebec2

  • Slightly more than half of Quebecers aged 12 and over have at least one chronic disease.
  • 16.3% of Quebecers aged 12 and over have hypertension, and 6% have diabetes.
  • Cardiovascular disease is the leading cause of hospitalization in Quebec.
  • Asthma affects close to 9% of Quebecers aged 12 and over, and 3.4% have COPD (chronic obstructive pulmonary disease).
  • More than 10% of Quebecers aged 12 and over have arthritis.

1 The CSSS Bordeaux-Cartierville-Saint-Laurent, the CSSS de St-Léonard et Saint-Michel, the CSSS du Coeur-de-l'Île, the CSSS Jeanne-Mance and the CSSS de la Pointe-de-l'Île.
2 Source: Rapport d'appréciation de la performance du système de santé et de services sociaux 2010 - État de situation portant sur les maladies chroniques et la réponse du système de santé et de services sociaux. Commissaire à la santé et au bien-être. March 2010. 136 p.


For further information:

For media requests:    

Stéphane Dion
NATIONAL Public Relations
418-648-1233, ext. 235

For further information, please contact:

Michelle Dubuc 
514-873-2114, ext. 235 
        Julie-Catherine Racine 
Pfizer Canada 

Profil de l'entreprise


Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.